Journals / Uluslararası Hematoloji-Onkoloji Dergisi / 2013 / Cilt: 23 - Sayı: 3

Beta Talasemili Hastalarda Sık Görülen Komplikasyonlar

Common Complications in Beta-Thalassemia Patients

Pages
193–199
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Mortality occurred in one (1.5%) out of 67 ß-thalassemia patient due to dilated cardiomyopathy and fatal arrhythmia.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Even the life span has prolonged for the last 40 years, increase in frequently seen complications with increasing age negatively affect the life quality of thalassemia patients.
📊
Key Findings & Data:In our study, complications encountered in 67 ß-thalassemia patients who were followedup at our hospital between 1 January 2004 and 31 May 2009 were retrospectively analyzed.
💡
Conclusion & Impact:Mortality occurred in one (1.5%) out of 67 ß-thalassemia patient due to dilated cardiomyopathy and fatal arrhythmia.
🔬Design:Research Article
📍Scope:2004 Verileri
⚙️Variables:Domain Parameters

Abstract

Even the life span has prolonged for the last 40 years, increase in frequently seen complications with increasing age negatively affect the life quality of thalassemia patients. In our study, complications encountered in 67 ß-thalassemia patients who were followedup at our hospital between 1 January 2004 and 31 May 2009 were retrospectively analyzed. Fifty-six patients were followed up with diagnosis of thalassemia major and 11 with thalassemia intermedia. Totally, 56.7% of patients were male and 43.3% were female. Ages varied between 2-20 years with the mean age of 10.3±4.8 years. Mean ferritin level was 2212±1370 ng/mL (41-6263 ng/mL) for 4.5 years. Complications were increased with increasing age. Complication rates were significantly higher among thalassemia major patients compared to thalassemia intermedia patients. There was no statistically significant relationship between complications and mean ferritin levels. The most common complications were endocrine complications (38.8%). Cardiac complications developed in 22.4% of the patients; gastroenterological complications in 19.4%; allergic complications in 9%; infectious complications in 1.5%; and thrombosis was detected in 1.5%. The endocrine complications were osteoporosis, growth retardation, developmental delay, short stature, hypothyroidism, delayed puberty, hypogonadism, and diabetes mellitus. The cardiac complications were left ventricular wall hypertrophy, diastolic dysfunction, systolic dysfunction, heart failure, pericardial effusion, dilated cardiomyopathy, left ventricular dilatation, left atrial dilatation, and fatal arrhythmias. Mortality occurred in one (1.5%) out of 67 ß-thalassemia patient due to dilated cardiomyopathy and fatal arrhythmia.

Özet

Talasemi hastalarının son 40 yıl içerisinde yaşam sürelerinde uzama olmakla birlikte yaş arttıkça görülen komplikasyonlar hastaların yaşam kalitelerini olumsuz yönde etkilemektedir. Çalışmamızda 1 Ocak 2004-31 Mayıs 2009 tarihleri arasında hastanemizde takipli 67 ß-talasemi hastasında görülen komplikasyonlar retrospektif olarak incelenmiştir. Çalışmaya dahil edilen hastaların 56’sı talasemi majör, 11’i talasemi intermedia tanısıyla takip edilmektedir. Olguların %56.7’si erkek, %43.3’ü kız idi. Yaşları 2-20 yıl arasında olup, yaş ortalamaları 10.3±4.8 yıl olarak hesaplandı. Hastaların 4.5 yıl boyunca bakılan ortalama ferritin düzeyleri 2212±1370 ng/mL (41- 6263 ng/mL) olarak bulundu. Hastaların komplikasyonlarında yaşla birlikte artış olduğu saptandı. Komplikasyonlar talasemi majörlü hastalarda talasemi intermedialı hastalara göre istatistiksel olarak anlamlı derecede daha sık görüldü. Ortalama ferritin değeri ile komplikasyon gelişme sıklığı arasında istatistiksel olarak anlamlı bir ilişki bulunmadı. Hastalarımızda en sık rastlanan komplikasyonlar %38.8 oranı ile endokrin komplikasyonlardı. Olguların %22.4’ünde kardiyak, %19.4’ünde gastroenterolojik, %9’unda allerjik, %1.5’inde enfeksiyöz komplikasyonlar ve %1.5’inde tromboz saptandı. Endokrin komplikasyonlar osteoporoz, büyüme-gelişme geriliği, boy kısalığı, hipotiroidi, puberte gecikmesi, hipogonadizm ve diyabetes mellitus idi. Kardiyak komplikasyonlar olarak sol ventrikül duvar kalınlaşması, diyastolik disfonksiyon, sistolik disfonksiyon, kalp yetmezliği, perikardiyal efüzyon, dilate kardiyomiyopati, sol ventrikül genişlemesi, sol atrium genişlemesi ve fatal aritmi görüldü. Çalışma süresi içerisinde 67 ß-talasemi hastasından biri (%1.5) fatal aritmi ve kardiyomiyopati nedeni ile kaybedildi.

🔖

Cite This Article

YAMAN, A., IŞIK, P., YARALI, H. N., KARADEMİR, S., ÇETİNKAYA, S., BAY, A., ÖZKASAP, S., KARA, A., TUNÇ, B. (2013). Beta Talasemili Hastalarda Sık Görülen Komplikasyonlar. Uluslararası Hematoloji-Onkoloji Dergisi, Cilt: 23 - Sayı: 3, 193–199. https://ajindex.com/articles/323174

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Weatherall DJ. Disorders of globin synthesis: The thalassemias. In: Lichtman MA, Beutler E, Kipps TJ, Seligsohn U. Williams Hematology, 7th ed. Newyork: McGraw-Hill Book Company; 2006: 633-667
  2. T.C. Sa¤l›k Bakanl›¤› AÇSAP Genel Müdürlü¤ü. Hemoglobinopati kontrol program›: Canatan D, Ayd›nok Y. Talasemi ve hemoglobinopatiler, Tan› ve Tedavi. Retma Matbaa Ltd, Antalya; 2007: 29
  3. Cunningham MJ, Sankaran VG, Nathan DG, Orkin SH. The Thalassemias. In: Orkin SH, Nathan DG, Ginsburg D, Look AT. Nathan and Oski’s Hematology of Infancy and Childhood, 7th ed. Philadelphia: Sounders Elsevier; 2009:1015-1109 4. Olivieri NF, Brittenham GM. Iron chelating therapy and the treatment of thalassemia. Blood 89: 739-761, 1997
  4. Maggio A, Capra M, Pepe A, et al. A critical review of non invasive procedures for the evaluation of body iron burden in thalassemia major patients. Pediatr Endocrinol Rev 6: 193-203, 2008
  5. Molyvda-Athanasopoulou E, Sioundas A, Karatzas N, et al. Bone mineral density of patients with thalassemia major: four-year follow-up. Calcified Tissue International 64: 481-484, 1999
  6. Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Survival and complications in thalassemia. Ann NY Acad Sci 1054: 40-47, 2005
  7. Angastiniotis M, Pavlides N, Aristidou K, et al. Bone pain in thalassemia: assesment of DEXA and MRI findings. J Pediatr Endocrinol Metab 11: 779-784, 1998
  8. Jensen CE, Tuck SM, Agnew JE, et al. High incidence of osteoporosis in thalassemia major. J Pediatr Endocrinol Metab 11: 975- 977, 1998
  9. Cario H, Stahnke K, Sander S, Kohne E. Epidemiological situation and treatment of patients with thalassemia major in Germany: results of the German multicenter beta-thalassemia study. Ann Hematol 79: 7- 12, 2000
  10. Low LC. Growth, puberty and endocrine function in beta-thalassaemia major. J Pediatr Endocrinol Metab 10: 175- 184, 1997
  11. Saka N, Sukur M, Bundak R, et al. Growth and puberty in thalassemia major. J Pediatr Endocrinol Metab 8: 181-186, 1995
  12. Aydinok Y, Darcan S, Polat A, et al. Endocrine complications in patients with beta-thalassemia major. J Trop Pediatr 48: 50-54, 2002
  13. Mohammadian S, Bazrafshan HR, Sadeghi-Nejad A. Endocrine gland abnormalities in thalassemia major: a brief review. J Pediatr Endocrinol Metab 16: 957-964, 2003
  14. Zervas A, Katopodi A, Protonotariou A, et al. Assesment of thyroid function in two hundred patients with beta thalassemia major. Tyroid 12: 151-154, 2002
  15. Borgna-Pignatti C, Rugol